testosterone sustanon

A has antiviral activity by inducing the cells in a state of resistance to viral infections and modulating the response of the immune system to neutralize viruses or destroy cells infected by them. Testosterone sustanon has antiproliferative effects on a number of human tumors in vitro and suppresses the growth of several human tumor xenografts in athymic mice with a mutation nude.

Clinical efficacy
in the human tumor, drug treated , decreased significantly the  synthesis,  and protein. A limited number of human tumor cell lines grown in vivo in nude mice with immune deficiency were tested for sensitivit . In vivo antiproliferative activity studied on tumors such as breast carcinoma, mucoid adenocarcinoma and colon poperechnoobodochnoy and blind, as well as prostate cancer. The degree of antiproliferative activity varies.

A leads to clinically significant tumor regression or disease stabilization in patients with hairy cell leukemia and AIDS patients with Kaposi’s sarcoma. Is also effective for the treatment of patients with multiple myeloma. Has activity in patients with advanced skin T cell lymphoma, which are insensitive, or are not suitable for conventional treatment.

Testosterone sustanon is effective for the treatment of patients with Ph-positive chronic myeloid leukemia (CML). eads to remission in 60% of patients with CML in chronic phase, regardless of previous treatment. Complete hematological remission still persists 18 months after the start of treatment in two thirds of patients studied. Unlike cytotoxic chemotherapy, interferon alpha-2a can lead to stable cytogenetic remission extending for more than 40 months.  And in combination with intermittent chemotherapy improves overall survival and delays the progression of the disease compared with the same chemotherapy.

In patients with non-Hodgkin’s lymphoma, low-grade in the appointment, in addition to chemotherapy (radiotherapy or without it)  prolongs disease-free survival and progression-free survival.

In patients with advanced renal cell carcinoma is the best therapeutic effect was observed in the appointment of high doses of the drug testosterone sustanon (36 million IU per day) as monotherapy or moderate dose  (18 million IU 3 times a week) in combination with vinblastine , compared to a monotherapy moderate doses of the drug  3 times a week. Patients treated with the drug monotherapy small dose (2 million IU / m2 per day), there was no effect of treatment. The combination of the drugwith vinblastine results in only a slight increase in the frequency of mild and moderate leukopenia and granulocytopenia compared with monotherapy. The duration of response and survival in monotherapy and combination therapy Roferon ® -A + vinblastine similar.  In combination with vinblastine more effective in survival as compared to a chemotherapy. In patients with advanced malignant melanoma treatment with resulted in objective tumor regression of cutaneous and visceral localization. Also  increases the length of time without disease recurrence in patients without lymph node involvement and distant metastases following resection of a melanoma (tumor thickness> 1.5 mm).

Testosterone sustanon in combination with Avastin as first-line therapy in patients with advanced and / or metastatic renal cell carcinoma as compared to the combination  placebo and significantly increases progression-free survival (PFS), disease and objective response rate. steroiden kaufen

steroide kaufen deutschland

anabolika steroide kaufen